Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
1993-12-16
2002-12-10
Goldberg, Jerome D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
Reexamination Certificate
active
06492352
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a method for the therapeutical and prophylactic control and treatment of acquired immunodeficiency syndrome (AIDS).
BACKGROUND OF THE INVENTION
In the late seventies a new disease was reported, which subsequently was referred to as Acquired Immuno Deficiency Syndrom (AIDS). It is now generally accepted that a retrovirus referred to as Human T-cell Leukemia Virus (HTLV-III) or Lymphadenopathy Associated Virus (LAV) plays an essential role in the etiology of AIDS. This virus will herebelow be denoted HTLV-III.
The full-blown AIDS is characterized by a profound immunodeficiency due to low numbers of a subset of lymphocytes-T-helper cells, which are the targets for HTLV-III lytic infections. The profound immunodeficiency, in the full-blown AIDS patients makes these patients highly susceptible to a variety of opportunistic infections of bacterial, fungal, protozoal or viral etiology. The etiological agents among viral opportunistic infections are often found in the herpes virus group, i.e., Herpes Simplex virus (HSV), Varicella Zoster virus (VZV), Epstein-Barr virus (EBV) and especially cytomegalo virus(CMV).
The discovery of HTLV-III as the likely cause of AIDS has presented a possible target for chemotherapy.
REFERENCES:
patent: 4215113 (1980-07-01), Eriksson et al.
patent: 4339445 (1982-07-01), Eriksson et al.
patent: 4536400 (1985-08-01), Helgstrand et al.
Samuel Broder et al., “A Pathogenic Retrovirus (HTLV-III) Linked to AIDS”, The New England Journal of Medicine, Nov. 15, 1984, pp. 1292-1297.
Luc Montagnier et al., “Lymphadenopathy Associated Virus and AIDS”, Clinical Immunology Newsletter, vol. 6, No. 5, May 1985, pp. 65-68.
Burgard, et al.,AIDS3:665-668 (1989).
Kaplan, et al.,Am. J. Med.82:615-620 (1987).
Cheson, et al.,J. Am. Med. Assoc.258:1347-1351 (1987).
Eeftinck-Schattenkerk, et al.,Arch. Intern. Med.148:209-211 (1988).
Jacobson, et al.,J. Infect. Dis.158:862-865 (1988).
Reddy, et al.,J. Infect. Dis.166:607-610 (1992).
Fletcher, et al.,Antimicrobial Agents and Chemotherapy38:604-607 (1994).
Palestine, et al.,Annuals Intern. Med.115:665-673 (1991).
Kaiser, et al., Poster PB0842, 10th International Conference on AIDS, Yokohama (1994).
“Soon A Drug Against AIDS Will be Available”, Arbetet, Nov. 2, 1984.
John S. Oxford et al., Conquest of Viral Diseases, Elsevier Science Publishers B.V. May 1, 1985, p. 591.
Eric G. Sandstrom et al., “Inhibition of Human T-Cell Lymphotropic Virus Type III In Vitro by Phosphonoformate”, The Lancet, Jun. 29, 1985, pp. 1480-1482.
Astra Lakemedel Aktiebolag
Goldberg Jerome D
White & Case LLP
LandOfFree
Method for the control and treatment of acquired... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the control and treatment of acquired..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the control and treatment of acquired... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2970802